Your browser doesn't support javascript.
loading
Fc engineered ACE2-Fc is a potent multifunctional agent targeting SARS-CoV2.
Wines, Bruce D; Kurtovic, Liriye; Trist, Halina M; Esparon, Sandra; Lopez, Ester; Chappin, Klasina; Chan, Li-Jin; Mordant, Francesca L; Lee, Wen Shi; Gherardin, Nicholas A; Patel, Sheila K; Hartley, Gemma E; Pymm, Phillip; Cooney, James P; Beeson, James G; Godfrey, Dale I; Burrell, Louise M; van Zelm, Menno C; Wheatley, Adam K; Chung, Amy W; Tham, Wai-Hong; Subbarao, Kanta; Kent, Stephen J; Hogarth, P Mark.
Afiliação
  • Wines BD; Immune therapies Laboratory, Burnet Institute, Melbourne, VIC, Australia.
  • Kurtovic L; Life Sciences, Burnet Institute, Melbourne, VIC, Australia.
  • Trist HM; Department of Immunology and Pathology, Central Clinical School, Monash University, Melbourne, VIC, Australia.
  • Esparon S; Department of Clinical Pathology, The University of Melbourne, Parkville, VIC, Australia.
  • Lopez E; Life Sciences, Burnet Institute, Melbourne, VIC, Australia.
  • Chappin K; Department of Immunology and Pathology, Central Clinical School, Monash University, Melbourne, VIC, Australia.
  • Chan LJ; Immune therapies Laboratory, Burnet Institute, Melbourne, VIC, Australia.
  • Mordant FL; Immune therapies Laboratory, Burnet Institute, Melbourne, VIC, Australia.
  • Lee WS; Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, VIC, Australia.
  • Gherardin NA; Immune therapies Laboratory, Burnet Institute, Melbourne, VIC, Australia.
  • Patel SK; Infectious Diseases and Immune Defence Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.
  • Hartley GE; Department of Medical Biology, The University of Melbourne, Melbourne, VIC, Australia.
  • Pymm P; Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, VIC, Australia.
  • Cooney JP; Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, VIC, Australia.
  • Beeson JG; Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, VIC, Australia.
  • Godfrey DI; Department of Medicine, Austin Health, The University of Melbourne, Melbourne, VIC, Australia.
  • Burrell LM; Department of Immunology and Pathology, Central Clinical School, Monash University, Melbourne, VIC, Australia.
  • van Zelm MC; Infectious Diseases and Immune Defence Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.
  • Wheatley AK; Department of Medical Biology, The University of Melbourne, Melbourne, VIC, Australia.
  • Chung AW; Infectious Diseases and Immune Defence Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.
  • Tham WH; Department of Medical Biology, The University of Melbourne, Melbourne, VIC, Australia.
  • Subbarao K; Life Sciences, Burnet Institute, Melbourne, VIC, Australia.
  • Kent SJ; Department of Immunology and Pathology, Central Clinical School, Monash University, Melbourne, VIC, Australia.
  • Hogarth PM; Department of Medicine, Royal Melbourne Hospital, The University of Melbourne, Parkville, VIC, Australia.
Front Immunol ; 13: 889372, 2022.
Article em En | MEDLINE | ID: mdl-35967361
ABSTRACT
Joining a function-enhanced Fc-portion of human IgG to the SARS-CoV-2 entry receptor ACE2 produces an antiviral decoy with strain transcending virus neutralizing activity. SARS-CoV-2 neutralization and Fc-effector functions of ACE2-Fc decoy proteins, formatted with or without the ACE2 collectrin domain, were optimized by Fc-modification. The different Fc-modifications resulted in distinct effects on neutralization and effector functions. H429Y, a point mutation outside the binding sites for FcγRs or complement caused non-covalent oligomerization of the ACE2-Fc decoy proteins, abrogated FcγR interaction and enhanced SARS-CoV-2 neutralization. Another Fc mutation, H429F did not improve virus neutralization but resulted in increased C5b-C9 fixation and transformed ACE2-Fc to a potent mediator of complement-dependent cytotoxicity (CDC) against SARS-CoV-2 spike (S) expressing cells. Furthermore, modification of the Fc-glycan enhanced cell activation via FcγRIIIa. These different immune profiles demonstrate the capacity of Fc-based agents to be engineered to optimize different mechanisms of protection for SARS-CoV-2 and potentially other viral pathogens.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Enzima de Conversão de Angiotensina 2 / COVID-19 Limite: Humans Idioma: En Revista: Front Immunol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Austrália

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Enzima de Conversão de Angiotensina 2 / COVID-19 Limite: Humans Idioma: En Revista: Front Immunol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Austrália
...